Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Hederacolchiside A1 (Raddeanoside R13) shows anti-leishmanial activity, it exhibits a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential. Hederacolchiside A1 shows antiproliferation activities in three cancer cell lines with the IC50 value of 2.4 uM, it exhibits a preferential cytotoxicity on a pigmented melanoma cell line. It suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 71.00 | |
5 mg | In stock | $ 165.00 | |
10 mg | In stock | $ 246.00 | |
25 mg | In stock | $ 413.00 | |
50 mg | In stock | $ 613.00 | |
100 mg | In stock | $ 873.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 278.00 |
Description | Hederacolchiside A1 (Raddeanoside R13) shows anti-leishmanial activity, it exhibits a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential. Hederacolchiside A1 shows antiproliferation activities in three cancer cell lines with the IC50 value of 2.4 uM, it exhibits a preferential cytotoxicity on a pigmented melanoma cell line. It suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. |
Source |
Synonyms | Raddeanoside R13 |
Molecular Weight | 897.1 |
Formula | C47H76O16 |
CAS No. | 106577-39-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.3 mg/mL (92.89 mM ), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Hederacolchiside A1 106577-39-3 Apoptosis Cytoskeletal Signaling MAPK Microbiology/Virology PI3K/Akt/mTOR signaling Parasite mTOR PI3K MEK Akt ERK Mammalian target of Rapamycin Phosphoinositide 3-kinase Inhibitor PKB inhibit Protein kinase B Hederacolchiside A 1 Hederacolchiside A-1 Raddeanoside R13 inhibitor